No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms.
INTRODUCTION Tumor necrosis factor (TNF)-alpha and interleukin-6 ( IL-6 ) are significantly elevated in patients with congestive heart failure ( CHF ) .  Pentoxifylline , a xanthin-derived agent , is known to inhibit the production of TNF-alpha and IL-6 . Recent studies have shown that pentoxifylline produces an increase in ejection fraction , a decrease in left-ventricular chamber size and an improvement in clinical status in patients with idiopathic-dilated cardiomyopathy . Therefore , we studied the effects of pentoxifylline in ischemic , hypertensive and idiopathic-dilated cardiomyopathy . METHODS Primary endpoint was left-ventricular ejection fraction ( LVEF ) assessed by contrast 2D echocardiography . Secondary endpoints were concentrations of TNF-alpha , IL-6 , brain natriuretic peptide , maximal oxygen uptake ( VO(2 max ) ) assessed by cardiopulmonary exercise testing and Minnesota Living with Heart Failure Question naire score or New York Heart Association scale . RESULTS Forty-seven patients ( 31.9 % ischemic , 21.3 % hypertensive , 10.6 % ischemic and hypertensive , 36.2 % idiopathic-dilated cardiomyopathy ) were r and omly assigned to pentoxifylline 600 mg BID ( n=23 ) or placebo ( n=24 ) if they had a compensated CHF with a LVEF less than or equal to 40 % and had taken their st and ard treatment consisting of angiotensin-converting enzyme inhibitors , diuretics and beta-blockers for at least 3 months . Baseline demographic and clinical characteristics of each group were similar . Forty-one patients completed the study protocol and were analysed for primary and secondary endpoints . After 6 months of treatment , LVEF was unchanged in the pentoxifylline group compared with placebo ( 29+/-7 to 33+/-10 % vs. 27+/-9 to 34+/-9 % , respectively , P = NS ) . Also the secondary endpoints did not significantly change during follow-up . CONCLUSION Additional treatment with pentoxifylline is neutral with regard to left-ventricular function , inflammatory cytokines and symptoms in patients with ischemic , hypertensive and idiopathic-dilated cardiomyopathy
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .